Osang Healthcare Co.,Ltd
Osang Healthcare Co.,Ltd researches, develops, and sells various diagnostic biosensors in South Korea and internationally. The company offers diagnostic biosensors for blood glucose, hemoglobin A1c, cholesterol, immuno diagnosis, molecular diagnosis, and others. It also exports its products to approximately 110 countries worldwide. The company was formerly known as Infopia Co., Ltd. and changed i… Read more
Osang Healthcare Co.,Ltd (036220) - Net Assets
Latest net assets as of September 2024: ₩277.86 Billion KRW
Based on the latest financial reports, Osang Healthcare Co.,Ltd (036220) has net assets worth ₩277.86 Billion KRW as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩287.70 Billion) and total liabilities (₩9.84 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩277.86 Billion |
| % of Total Assets | 96.58% |
| Annual Growth Rate | 19.56% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 24.55 |
Osang Healthcare Co.,Ltd - Net Assets Trend (2022–2024)
This chart illustrates how Osang Healthcare Co.,Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Osang Healthcare Co.,Ltd (2022–2024)
The table below shows the annual net assets of Osang Healthcare Co.,Ltd from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩285.75 Billion | -2.48% |
| 2023-12-31 | ₩293.03 Billion | +46.62% |
| 2022-12-31 | ₩199.86 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Osang Healthcare Co.,Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 96.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩230.72 Billion | 80.74% |
| Common Stock | ₩7.34 Billion | 2.57% |
| Other Components | ₩47.69 Billion | 16.69% |
| Total Equity | ₩285.75 Billion | 100.00% |
Osang Healthcare Co.,Ltd Competitors by Market Cap
The table below lists competitors of Osang Healthcare Co.,Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
InspireMD Inc
NASDAQ:NSPR
|
$37.44 Million |
|
China Everbright Greentech Limited
F:CK7
|
$37.46 Million |
|
Vaccibody AS
F:5VB
|
$37.47 Million |
|
Banestes S.A - Banco do Estado do Espírito Santo
SA:BEES3
|
$37.47 Million |
|
Index Living Mall Public Company Limited
BK:ILM
|
$37.42 Million |
|
Pinar Sut Mamulleri Sanayi AS
IS:PNSUT
|
$37.42 Million |
|
Tobii AB
PINK:TBIIF
|
$37.41 Million |
|
Kolon Global Corp
KO:003075
|
$37.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Osang Healthcare Co.,Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 293,026,717,580 to 285,747,809,800, a change of -7,278,907,780 (-2.5%).
- Net loss of 11,364,443,360 reduced equity.
- Dividend payments of 25,168,660,000 reduced retained earnings.
- Share repurchases of 18,160,123,220 reduced equity.
- Other factors increased equity by 47,414,318,800.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-11.36 Billion | -3.98% |
| Dividends Paid | ₩25.17 Billion | -8.81% |
| Share Repurchases | ₩18.16 Billion | -6.36% |
| Other Changes | ₩47.41 Billion | +16.59% |
| Total Change | ₩- | -2.48% |
Book Value vs Market Value Analysis
This analysis compares Osang Healthcare Co.,Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.48x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.68x to 0.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | ₩14690.87 | ₩9930.00 | x |
| 2023-12-31 | ₩21539.68 | ₩9930.00 | x |
| 2024-12-31 | ₩20839.83 | ₩9930.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Osang Healthcare Co.,Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14.12%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.03x
- Recent ROE (-3.98%) is below the historical average (18.70%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 20.34% | 20.96% | 0.78x | 1.25x | ₩20.66 Billion |
| 2023 | 39.74% | 32.72% | 1.11x | 1.09x | ₩87.13 Billion |
| 2024 | -3.98% | -14.12% | 0.27x | 1.03x | ₩-39.94 Billion |
Industry Comparison
This section compares Osang Healthcare Co.,Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $87,040,140,684
- Average return on equity (ROE) among peers: 5.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Osang Healthcare Co.,Ltd (036220) | ₩277.86 Billion | 20.34% | 0.04x | $37.44 Million |
| Shinhung (004080) | $87.31 Billion | 3.50% | 0.52x | $10.80 Million |
| HansBiomed Corporation (042520) | $43.16 Billion | 11.38% | 0.21x | $246.58 Million |
| JVM Co. Ltd (054950) | $98.83 Billion | 10.23% | 0.72x | $117.37 Million |
| Huvitz Co. Ltd (065510) | $51.68 Billion | 16.97% | 0.32x | $43.64 Million |
| Vieworks Co. Ltd (100120) | $188.04 Billion | 17.80% | 0.28x | $101.54 Million |
| Corentec Co Ltd (104540) | $48.30 Billion | -3.04% | 0.46x | $40.80 Million |
| Hironic Co. Ltd (149980) | $40.72 Billion | 7.13% | 0.15x | $23.71 Million |
| Laseroptek Co., Ltd. (199550) | $-3.94 Billion | 0.00% | 0.00x | $21.68 Million |
| Humasis Co. Ltd (205470) | $229.26 Billion | -13.28% | 0.45x | $48.97 Million |